Chapter 186 The popular developer is officially launched!
Foreign-funded manufacturers led by Siemens and GE have long occupied 80% of China's CT market. It has never happened that a domestic manufacturer can sell 60 CT machines at one time.
After the words fell, the meeting with Siemens executives that had just begun became solemn.
Vice President Peter had no intention of stopping. He paused slightly and continued:
"Apart from their first batch of sales reaching nearly 60 units, the most troublesome thing is... we There is no countermeasure now, or we can’t come up with any competing products.”
"You can imagine, if you are the director of a hospital, would you like to purchase a CT machine that can not only perform traditional CT scans but also identify the 'nature of pulmonary nodules'? Or would you rather purchase a CT machine that can only complete traditional CT scans?" CT machine? The key is that the prices of these two CT machines are almost the same!”
“So, I can almost imagine, If this development continues, Elephant Medical will take away most of our share in the Chinese market in just two or three years, and our profits in the Chinese market after nearly 30 years of operation will plummet!"
< br>“This is not alarmist.”
The strict Germans in the conference room were silent, and everyone felt a strong crisis.
“This won’t work, we must find ways to deal with their threats.”
About ten seconds later, a blond German executive in the silent conference room took the lead in breaking the silence and spoke.
"Yes, I agree that we must find a way to deal with it! The Chinese market is very important to us, and we must not let them seize our share!"
"I agree too. "
After the blond senior executive finished speaking, two or three senior executives in the conference room also expressed their opinions in a deep voice.
But at this moment, a deep voice from among the senior executives suddenly sounded:
"I also agree to counterattack and cannot lose the Chinese market!"
"But what are the countermeasures we can come up with now?!"
"Qingshan Pharmaceutical has clearly refused to cooperate with If we cooperate, we simply cannot come up with the same type of product that can identify pulmonary nodules as Elephant Medical.”
After the words fell, the atmosphere in the conference room that had just been ignited suddenly fell silent again, and all the executives present were silent. He couldn't help but frowned.
That’s right.
In fact, Elephant Medical is not the key point. The technical level of Elephant Medical is just that. The real core and most important thing is Qingshan Pharmaceutical’s “Nano Nodule Developer”!
It’s because their “nodule developer” can identify whether pulmonary nodules are benign or malignant, thereby producing a fluorescence reaction. Elephant Medical’s CT machine only completes the capture of the fluorescence spectrum!
This time the silence lasted for nearly a minute, and finally an executive spoke again:
“Everyone, I think the only way to deal with this is to develop a It’s the same developer as Tsingshan Pharmaceutical’s ‘Nano Nodule Developer’.”
“Only in this way, only with the same type of products, can we truly counterattack with our many years of brand recognition. Like medical, compete with them! ”
Develop Siemens’ own “nodule developer”?
Everyone thought about it and nodded after a while.
But...
"I agree with this plan. After all, Qingshan Pharmaceutical has developed the 'nano-nodule developer', and its technical patents and technical routes are ours. It can be used as a reference.”
“It’s just...”
"We have no experience in drug research and development. If we really want to develop a 'nodule imaging agent' with similar functions, I am afraid we will have to cooperate with other professional pharmaceutical companies."
It has to be said, The executive's speech really clarified everyone's thinking.
If Siemens wants to maintain its current brand competitiveness and compete with Elephant Medical, it must launch a CT machine with similar functions to Elephant Medical's "nodule imaging CT machine" as soon as possible.
Obviously Qingshan Pharmaceutical’s “Nano Nodule Developer” cannot be used, so I will cooperate with other pharmaceutical companies to develop agents with similar functions!
This is the same as in other industries. Once a company develops a new feature that is well received, the best way is not to question it or to remain indifferent.
Instead, they try their best to follow the trend and imitate similar functions and products as soon as possible.
With the brand reputation Siemens has accumulated in China over the years, as long as products with similar functions are launched, the market share will naturally be stabilized.
With a clear idea, the ideas of several senior executives were completely opened up:
“It is indeed a feasible way for us to cooperate with professional pharmaceutical companies to develop agents similar to 'developer';< br>
Also, since the imaging agent is for pulmonary nodules, it is best to find a pharmaceutical company that develops pulmonary drugs. ”
"I know something about this. The best lung cancer drug research and development company in Europe and the world is the British company AstraZeneca."
"They focus on the research and development of targeted lung cancer drugs. The third generation lung cancer targeted drug 'Osimertinib' launched in a few years has become the best and most profitable lung cancer targeted drug in the world."
"I think we can contact AstraZeneca. ', and they started the research and development of nodule imaging agent."
AstraZeneca?
The seven senior executives present all know something about the pharmaceutical company "AstraZeneca", and "AstraZeneca" is indeed a good partner.
Not only are they highly professional, they are also headquartered in the UK, making communication very convenient.
Vice President Peter, the host of the meeting, also nodded slightly and immediately started to search for more specific operating information of "AstraZeneca" on the computer.
But when he saw the main profit composition of "AstraZeneca", Peter suddenly frowned.
After a moment, he coughed slightly and interrupted the senior executives who were having a heated discussion.
“Everyone, I think it’s difficult for us to cooperate with AstraZeneca.”
"It's difficult?"
"Yes."
Peter turned the laptop on the conference table to everyone and continued:
"This is 'AstraZeneca' The proportion of revenue in last year’s annual report, all of their Drug sales reached 44 billion U.S. dollars, of which oncology drug revenue reached 28 billion U.S. dollars... accounting for 63.6%. "In other words, lung cancer drugs are their most important source of profit!"
"The 'nodule imaging agent' we want to develop is strictly a lung cancer early screening agent. Once popularized on a large scale, it will inevitably reduce the incidence of lung cancer..."
Peter did not finish his words. , stopped abruptly.
But all the senior officials present understood the meaning of the second half.
The incidence of lung cancer has decreased, and the biggest impact is of course "AstraZeneca", the best-selling and largest lung cancer targeted drug pharmaceutical company in the world!
Don’t mention nonsense like “I wish there would be no disease in the world, I’d rather put medicine on the shelf”. Modern drug research and development and sales have already become a capital business, but the threshold is just a little higher. .
Previously, AstraZeneca was definitely unable to control the "nodule developer" developed by Tsingshan Pharmaceutical on its own, but if it were to cooperate with them in research and development, it would be absolutely impossible to cooperate.
The senior executives in the conference room couldn't help but feel a bit tricky. If AstraZeneca, the best lung cancer drug research and development company, cannot find a way, then are there any other suitable pharmaceutical companies?
Next, several executives discussed several other pharmaceutical companies, but either they were not good at research and development in the field of lung cancer, or they had huge interests in lung cancer drugs like "AstraZeneca".
The discussion suddenly reached a deadlock.
Fortunately at this moment, the blond executive who spoke first suddenly raised his hand and said:
"If it is difficult for pharmaceutical companies to cooperate, I have another suggestion. We can cooperate with some well-known lung cancer 'biological laboratories'!"
"As far as I know, 'AstraZeneca' is currently the most The star's third-generation targeted drug 'osimertinib' is also made with a family Developed in cooperation with biological laboratories. "
"If I remember correctly, it should be a biological laboratory in Norway that specializes in lung cancer viruses, called 'Adlev' Biological Laboratory." Norway, specializing in lung cancer viruses! The "Adelev" biological laboratory of lung cancer virus?
The eyes of the executives flashed brightly for the first time. There is no need to question the professionalism of this laboratory specializing in lung cancer viruses.
And unlike pharmaceutical companies, which have competing interests in targeted drugs, this is indeed a very good partner!
But just when all the executives were looking forward to getting more information about Adelev Biological Laboratory, the blond man suddenly paused and spoke in a lower tone:
"But , the Ph.D. in charge of this 'Adelev' biological laboratory has a somewhat special identity."
"He is an American and graduated from Harvard University, the best major in virus biology in the United States."< br>
“At the same time, he is a Jew.”
Jewish?
Working with Jewish Americans?
The discussion in the conference room stopped abruptly, and there was no need to say more about the Jewish sensitivity towards the Germans.
After a while, everyone looked at Mr. Tobias, the president who had been silent in the conference room.
Tobias was also slightly surprised, but he did not hesitate for too long.
The best solution is of course to "AstraZeneca" with the British, but it is obviously impossible for the British to do so at the moment.
But other pharmaceutical companies are not reassuring professionally.
Compared to the Jews, Siemens currently faces a more deadly threat.
About ten seconds later, he coughed lightly, glanced at the audience and said:
"No matter what the identity of the doctor behind the 'Adelev' biological laboratory is, let's contact him first. Get in touch.”
"Needless to say anything else, I hope everyone understands that if we don't act quickly, in two or three years, do you really think that we will only be affected by the Chinese market?"
After the words fell, the meeting There was silence in the room.
……
I have to say that Siemens Healthcare in Germany is indeed very efficient.
Under huge external pressure, they soon began preliminary cooperation negotiations with the "Adelev" Biological Laboratory.
Of course, Zhang Yang and Elephant Medical did not know that due to the emergence of the "nodule imaging CT machine", Siemens on the other side of the ocean had begun preparing a plan to imitate the "nodule imaging agent"!
Of course, even if he knew about Zhang Yang, he wouldn't care too much. At this moment, he and the Third People's Hospital have devoted themselves to the last 100 subjects of the third clinical phase of the "Nano Nodule Developer" in the sprint.
Thanks to Dr. Zhou’s recruitment of two more experienced surgeons, 100 subjects quickly began nodule surgery, and the pace of clinical phase III trials surged.
Ten days later, the surgeries on all 100 subjects were completed, which also means the end of the Phase III clinical trial of the "Nano Nodule Developer".
One month later, the "Nano Nodule Developer" developed by Tsingshan Pharmaceutical passed clinical trials and received production approval!
The next day, the official launch time of the "Nano Nodule Developer" was determined. At the same time, the price of a single developer was also set, 200 yuan/tube, one tube at a time.
In other words, if you are worried that your pulmonary nodules are malignant, all patients only need to spend an additional 200 yuan to do a "nodule imaging CT" to know whether their pulmonary nodules are in the early stage. Lung cancer!
As soon as possible, professional media immediately reported the news!
[Good news, a must read for all pulmonary nodule patients, good news for pulmonary nodule patients! 】
[The ‘nodule imaging agent’ developed by Qingshan Pharmaceutical will be officially launched soon. By then, patients with pulmonary nodules will no longer have to worry. They only need to take a ‘nodule imaging CT’ to determine the nature of the nodules! 】
[A source from a hospital revealed that the price of a ‘nodule imaging CT’ is about 700-900 yuan. 】
【Currently, this drug has not been included in medical insurance reimbursement. 】
The news quickly spread to the Internet and attracted the attention of countless netizens.
You must know that the number of patients with pulmonary nodules in China has increased sharply in the past two years. A large number of patients have discovered many pulmonary nodules through physical examinations in their units.
It’s okay to have a good attitude and follow the doctor’s instructions for follow-up examinations. But there are not a few people who are anxious because they can’t eat well or sleep well because of ground glass nodules. They have traveled all over the country to see countless doctors. !
And now!
It is finally on the market, and the price is not expensive and completely acceptable!
Netizens on the Internet are discussing it enthusiastically.
“700-900 yuan is totally acceptable! I originally thought it would be at least 1000-2000 yuan once! What a conscience!”
“Oh my god, it’s finally on the market, and the price is not the best. Importantly, I can finally know whether my lung nodules are early stage lung cancer!”
"Yes, I read that currently only the Third People's Hospital of Chengdu can perform the 'nodule imaging CT' scan. When will other hospitals open it? When will this function be available in my fifth-tier city? I also want to get a CT scan. Look!”
Not only are netizens discussing it, but major pulmonary nodule patient groups are also very lively.
Compared with the netizens who eat melons, most of the patients in these patient groups and Tieba groups are similar to Zhang Lao’s original situation. They are all nodule patients who are highly suspected of lung cancer, but they are forced to do so due to various reasons. I am still debating whether to have surgery or not.
After all, the number of subjects recruited for the clinical trial of Tsingshan Pharmaceutical's "Nano Nodule Developer" was only a small number, and the recruitment requirements were strict, so most people did not get a spot.
It’s fine now!
No need to grab it!
"Dear patients, Qingshan Pharmaceutical's 'Nano Nodule Developer' has been launched. Currently, only the Third People's Hospital of Chengcheng can take 'Development CT' at the first time!"
"I just asked about the price. It only costs 800 yuan a time. Any doctor in the thoracic surgery department can issue a bill. If you want to take pictures, please register immediately!” Register, I can’t wait!”
"I'll go too!"
......
On the other side, a tertiary hospital in a fourth-tier city.
“This patient, it is really difficult to judge whether the pulmonary nodules in your case are benign or malignant. If you perform surgery rashly, it is very risky, and I am also worried that you will suffer a wasted operation.”
"Hey, doctor, thank you for thinking about me, but I am really worried about lung cancer, and several doctors said it might be lung cancer. After thinking about it, I still think I should have surgery! If the cut is wrong, the cut is wrong. ”
The doctor suddenly smiled and then slowly shook his head.
“In the past, maybe this was the only way to do it, but now there are new advances in medicine.”
“Have you been to Chengdu? It’s about 300 kilometers away from us. Remember it? At the hospital address, a CT scan can be performed to detect pulmonary nodules. You can tell whether it is malignant or benign by taking one! "
"Huh?"
The patient was surprised, his eyes were full. A flash of hope!
"Doctor, I know in Chengdu. Which hospital are you talking about? West China?"
"No, it's the Third People's Hospital in Chengdu. Go ahead and register for a 'development CT' Look!”
“Rongcheng Third People’s Hospital?”
“Thank you, thank you doctor!”
……
(End of this chapter)